Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments

Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments

Background Symptom Screening in Pediatrics Tool (SSPedi) was developed for symptom screening by children 8-18 years. Objectives were to evaluate the reliability and validity of proxy-SSPedi and self-report mini-SSPedi for younger children. Methods This multi-center study enrolled guardians of childr...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2022-07, Vol.22 (1), p.1-730, Article 730
Main Authors: Tomlinson, Deborah, Dupuis, L. Lee, Johnston, Donna L, Kuczynski, Susan, Patel, Serina, Schechter, Tal, Vettese, Emily, Mairs, Mark, Tomlinson, George A, Sung, Lillian
Format: Article
Language:eng
Subjects:
Acute lymphoblastic leukemia
Age
Analysis
Cancer
Cancer in children
Cancer therapies
Care and treatment
Children
Children & youth
Evaluation
Health aspects
Hematopoietic stem cells
Likert scale
Medical equipment
Mucositis
Nausea
Oncology, Experimental
Patients
Pediatrics
Physiological apparatus
Proxy
Quality of life
Quantitative psychology
Reliability
Responsiveness
Symptom screening
Transplantation
Validity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Symptom Screening in Pediatrics Tool (SSPedi) was developed for symptom screening by children 8-18 years. Objectives were to evaluate the reliability and validity of proxy-SSPedi and self-report mini-SSPedi for younger children. Methods This multi-center study enrolled guardians of children 2-7 years receiving cancer treatments (proxy-SSPedi) and their children 4-7 years (mini-SSPedi). The two populations were: (1) More symptomatic group where children were receiving active cancer treatment and were in hospital or clinic for four consecutive days; and (2) Less symptomatic group where children were receiving maintenance therapy for acute lymphoblastic leukemia or had completed cancer therapy. Proxy-SSPedi or mini-SSPedi were completed with measures of mucositis, nausea, pain, quality of life and overall symptoms. Respondents in the more symptomatic group repeated proxy-SSPedi/mini-SSPedi and a global symptom change scale 3 days later. Results There were 402 guardians and 326 children included in the analysis. Test re-test reliability of proxy-SSPedi showed intraclass correlation coefficient (ICC) 0.83 (95% confidence interval (CI) 0.72-0.90). Mean difference in proxy-SSPedi between more and less symptomatic groups was 9.7 (95% CI 8.3-11.1). Proxy-SSPedi was responsive to change and hypothesized relationships between measures were observed. With a priori threshold [greater than or equai to]0.6, inter-rater ICC among all dyads and those 6-7 years were 0.54 (95% CI 0.45-0.62) and 0.62 (95% CI 0.50-0.71) respectively. Among participating children, other hypothesized reliability and validity thresholds were generally met. Conclusions Proxy-SSPedi is reliable, valid and responsive in children 2-7 years old receiving cancer treatments. Mini-SSPedi can be used for children 6-7 years of age. Keywords: Symptom screening, Children, Validity, Reliability, Responsiveness, Proxy, Oncology, Hematopoietic stem cell transplantation
ISSN:1471-2407
1471-2407